97% INCREASED PROBABILITY OF WOUND HEALING
USING APLIGRAF® COMPARED TO EPIFIX®1a
|
|
 |
| |
A COMPARATIVE EFFECTIVENESS ANALYSIS OF APLIGRAF VERSUS EPIFIX IN THE TREATMENT OF DIABETIC FOOT ULCERS (DFUs) IN A REAL-WORLD SETTING1
|
|
 |
| | Objective |
 |
To compare the real-world effectiveness of Apligraf and EpiFix for the treatment of DFUs
|
 |
| | Evaluated |
|
Incidence of and time to closure for wounds treated in 2014
|
|
| | Methodology |
|
Retrospective analysis of all available data in 2014 from Net Health's electronic medical record databasec
|
|
99 wound care centers contributed data
|
|
| |
| Population |
 |
|
|
DFUs between 1 cm2-25 cm2 with ≤1-year duration and ≤20% area reduction in the 2 weeks prior to first treatment were analyzed
|
|
| |
APLIGRAF CLOSED MORE WOUNDS
|
|
| |
APLIGRAF CLOSED WOUNDS FASTER
|
|
| |
FEWER APPLICATIONS AND FASTER HEALING RESULTS IN POTENTIAL COST SAVINGS
|
|
|
| |
• Using Apligraf to heal chronic DFUs
compared to EpiFix may save over $7,0002,3
|
|
| |
EpiFix is a registered trademark of MiMedx Group, Inc.
a Hazard Ratio = 1.97 [95% confidence interval 1.17, 3.33].
b Estimated incidence of and median time to wound closure and P value are from a Cox regression model with terms for treatment, baseline wound area, duration, depth, and location. All 2014 data were included in the analysis. P=0.01.
c WoundExpert®, Net Health, Pittsburgh, Pennsylvania.
d Estimated incidence of wound closure and P value are from a Cox regression model with terms for treatment, baseline wound area, duration, depth, and location. All 2014 data were included in the analysis.
e Estimated median time to wound closure and P value are from a Cox regression model with terms for treatment, baseline wound area, duration, depth, and location. All 2014 data were included in the analysis.
|
|
|
|
|
| |
De-identified patient data released to Organogenesis was consistent with the terms and conditions of Net Health's participating client contracts and the requirements
of HIPAA. Net Health was not involved in any way in the analysis, interpretation, or reporting of the data.
1. Kirsner RS, Sabolinski ML, Parsons NB, Skornicki M, Marston WA. Comparative effectiveness of a bioengineered living cellular construct vs a dehydrated human amniotic membrane allograft for the treatment of diabetic foot ulcers in a real world setting. Wound Repair Regen. Accepted article. doi:10.1111/wrr.12332. 2. Epifix®. CY 2015 Hospital Outpatient Medicare Reimbursement. Marietta, GA: MiMedx Inc; 2014. 3. Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons NB. Burden of diabetic foot ulcers for medicare and private insurer. Diabetes Care. 2014; 37(3):651-658.
For information on support programs and tools available from Organogenesis Inc.,
call 1.888.HEAL.2.DAY (1.888.432.5232-Option 1)
Please see complete prescribing information at www.Apligraf.com
|
|
 |
©2015 Organogenesis Inc. OI-A1183
All rights reserved. Printed in U.S.A. 7/15
Apligraf is a registered trademark of Novartis. EpiFix is a registered trademark of MiMedx Group, Inc.
Please see complete prescribing information at www.Organogenesis.com.
|
 |
|
|
This email was sent to: %%Email Address%%
This email was sent by: %%Member_Busname%%
%%Member_Addr%% %%Member_City%%, %%Member_State%% %%Member_PostalCode%%
%%Member_Country%% |
We respect your right to privacy - view our policy |
|
|
|
